NCT03357185 (Eversion) is a clinical trial of Femoral eversion in Atheromatous, sponsored by Hôpital NOVO.

Who is sponsoring NCT03357185?

NCT03357185 is sponsored by Hôpital NOVO.

What drugs are being tested in NCT03357185?

Interventions in NCT03357185: Femoral eversion.

What condition does NCT03357185 study?

NCT03357185 studies Atheromatous.

Is NCT03357185 still recruiting?

NCT03357185 is currently completed. Last updated 29 July 2019.

Last reviewed 2019-07-29 · How we verify

NCT03357185: Eversion

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Prospective Evaluation of Femoral Tripod Eversion Technique

Completed Last updated 29 July 2019

What this trial tests

trial testing Femoral eversion in Atheromatous in 37 participants. Completed in 30 September 2017.

Timeline

1 June 2014

Primary endpoint
30 April 2016

30 September 2017

Quick facts

Lead sponsor	Hôpital NOVO
Status	Completed
Study type	OBSERVATIONAL
Enrollment	37
Start date	1 June 2014
Primary completion	30 April 2016
Estimated completion	30 September 2017

Drugs / interventions tested

Femoral eversion

Conditions studied

Atheromatous — all drugs for Atheromatous →

Sponsor

Hôpital NOVO — full company profile →

Who can join

18 and older, any sex, with Atheromatous. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Endarteriectomy is considered as the first line treatment of femoral bifurcation atheromatous lesions. Eversion technique, similar to that used for carotid bifurcation, is safe and possible for the majority of the femoral tripod lesions. The major advantage of the eversion technique is the absence of prosthetic material to be performed. However, its use has been scarcely evaluated in the literature to date. This work aims at evaluating the long term safety and the efficacy of eversion femoral technique. Surgical technique was thoroughly described and participants were followed up for two years by serial clinical and doppler US examination.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Atheromatous

Currently open trials in the same condition.

NCT06226844 — Can the BeatMove Device Help Patients With Obliterative Arterial Disease of the Lower Limbs? · NA · recruiting

Other Hôpital NOVO trials

Trials by the same sponsor.

NCT07394478 — Study of the Association Between Sacroiliitis/Axial Spondylarthritis and Giant Cell Arteritis/ Polymyalgia Rheumatica · not yet recruiting
NCT07412340 — Disarticulation Septoplasty Versus Classical Way · not yet recruiting
NCT07298070 — Functional and Aesthetic Outcomes Following Lower Lip Reconstruction · not yet recruiting
NCT07257094 — Nasal Reconstruction FACE-Q : French Validation of the Nasal Reconstruction FACE-Q Questionnaire for Reconstruction/Reha · recruiting
NCT07505706 — Patient Journey in Palliative Care Within the NOVO Hospital Group. · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03357185 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Hôpital NOVO
Last refreshed: 29 July 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03357185.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing